Phase
Condition
Epilepsy
Tardive Dyskinesia
Dystonias
Treatment
Sham TMS3 stimulation
rTMS of left or right angular gyrus (AG) or frontal cortex (FC)
Anodal tDCS of left or right AG or FC
Clinical Study ID
Ages 18-65 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
(Healthy Controls)
- Fluent in English
(Patients with PMD or PNES):
Diagnosis of PMD/PNES confirmed by a neurologist with expertise in movementdisorders.
Per the treating neurologist, subject is unlikely to require treatment and/or dosagechanges for 3-6 months following screening
Exclusion
Exclusion Criteria:
Any history of a significant neurological disorder, which may interfere with theinterpretation of study data, as determined by the PI
Chronic or progressive medical condition
Any history of traumatic brain injury or significant head trauma
Currently meets criteria for substance abuse or dependence
History of any psychotic disorder or other psychiatric condition which may interferewith data interpretation
Pregnancy
Metal or devices in the head, including neurostimulators or metal foreign bodies
Any other implanted metal device, including pacemaker, spinal cord stimulator, VNS.
Any other ferromagnetic substance in the body that may increase study risk (including dental prosthetics, etc.).
Taking tricyclic antidepressant or antiepileptic medications or CNS active drugsunder "strong potential hazard" list in Rossi et al., 2009
Current diagnosis of any inflammatory or autoimmune disorder within last 6 months
PMD and PNES Patients
Any history of traumatic brain injury or significant head trauma
Diagnosis of organic seizure disorder, including febrile seizures and tonic-clonicseizures;
Neurological disorder other than PMD and PNES including stroke, fainting spells orsyncope of unknown cause(s);
Major or unstable medical illness, especially any current diagnosis of inflammatoryor autoimmune disorders within last 6 months
Metal or devices in the head, including neurostimulators or metal foreign bodies
Taking tricyclic antidepressant medications or CNS active drugs under "strongpotential hazard" list in Rossi et al., 2009;
Diagnosis of dementia, or Montreal Cognitive Assessment (MoCA) ≤24;
Recurrent visual hallucinations, within the past 6 months;
History of significant uncontrollable movements of the head;
Any clinically significant abnormality on vital signs
Study Design
Study Description
Connect with a study center
New York University School of Medicine
New York, New York 10016
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.